Introduction {#Sec1}
============

Liver cirrhosis is defined as the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury, and is associated with the development of liver failure and portal hypertension^[@CR1],[@CR2]^. Infection with Hepatitis B (HBV) or C (HCV), alcohol abuse and nonalcoholic fatty liver disease (NAFLD) are the main etiologic factors of liver cirrhosis worldwide^[@CR1],[@CR2]^. However, certain genetic polymorphisms may influence the progression of liver fibrosis^[@CR3]^.

The vitamin D receptor (*VDR*) is a DNA-binding transcription factor that is expressed on peripheral blood (PB) monocytes and activated T lymphocytes. *VDR* belongs to the nuclear receptor superfamily and is associated with many physiological processes^[@CR4]--[@CR6]^. The most common polymorphisms of the *VDR* gene are the BsmI, FokI, TaqI and ApaI. FokI, is located in exon 2 of the *VDR* gene and the presence of this polymorphism results in a shortened VDR protein due to an alteration in the start codon^[@CR7]^. The ApaI and the BsmI polymorphisms are located in intron 8 at the 3′ end of the *VDR* gene. These polymorphisms do not change the amino acid sequence of the VDR protein. However, BsmI and ApaI may affect gene expression through the alteration of mRNA stability, the disruption of splice sites for mRNA transcription, or a change in intronic regulatory elements^[@CR8],[@CR9]^. The TaqI polymorphism is located in exon 9 at the 3′ end of the human *VDR* gene and results in a synonymous change due to a nucleotide substitution. The presence of TaqI polymorphism does not modify the VDR protein but is involved in the regulation of the stability of *VDR* mRNA^[@CR8],[@CR9]^. Recent studies have shown that there is a genetic association of *VDR* polymorphisms to autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), HBV infection and hepatocellular carcinoma (HCC)^[@CR8],[@CR10]--[@CR17]^. Moreover, the progression of liver fibrosis has been associated with the existence of *VDR* polymorphisms in patients with PBC^[@CR10]^ and HCV^[@CR18]^ and with reduced full-length VDR protein expression, but increased VDR protein fragments in patients with NAFLD^[@CR10],[@CR18],[@CR19]^.

Cytokines are key mediators in the pathophysiology of liver disease as they play an essential role in hepatic regeneration and fibrosis^[@CR20]^. The hepatic non parenchymal cells which are involved in liver fibrosis development, can rapidly produce profibrogenic cytokines which lead to hepatic inflammation and fibrosis^[@CR21]^. In contrast, antifibrogenic cytokines downregulate the pro-inflammatory response promoting the hepatic regeneration^[@CR20],[@CR21]^. *VDR* polymorphisms may influence the immune regulation by affecting cytokine levels and, thus, they might play a role in the progression of liver disease^[@CR11],[@CR13]^.

In this study, we have investigated the potential associations between *VDR* gene polymorphisms and the severity of liver cirrhosis, in relation to the cytokine and bacterial profiles, vitamin D and vitamin D binding protein (VDBP) levels, and their role on patient survival.

Results {#Sec2}
=======

The main demographic and clinical characteristics of the examined patients are presented in Table [1](#Tab1){ref-type="table"} and the main characteristics of the examined *VDR* polymorphisms are presented in Table [2](#Tab2){ref-type="table"}.Table 1Patients' demographic and main clinical baseline characteristics.MeanRangeAge (years)60.7429--84**NPercentage (%)**Sex (M/F)60/2967.4/32.6**Etiology of liver cirrhosisNPercentage (%)**Alcohol consumption3236.4HBV ± HDV infection2932.5HCV infection1010.4Cryptogenic cirrhosis66.5Autoimmune hepatitis55.2Primary biliary cirrhosis33.9Nonalcoholic steatohepatitis22.6Primary sclerosing cholangitis11.3HBV infection + HCV infection11.3**Median (IQR)**Vitamin D levels (ng/mL)21.1 (14.7, 31.6)Hb (g/dL)12.7 (11.2, 13.8)Plt (K/uL)117.5 (66, 160)INR1.3 (1.1, 1.6)Creatinine (mg/dL)0.9 (0.7, 1.1)SGPT (U/L)31.0 (21.0, 58.0)G-GT (U/L)54.0 (29.0, 109.0)ALP (U/L)101.5 (76.0, 142.0)Albumin (g/dL)3.6 (3.0, 4.0)Total Bilirubin (mg/dL)1.3 (0.7, 2.5)K (mmol/L)4.3 (3.9, 4.7)Na (mmol/L)138.4 (135.2, 141.0)Ca (mmol/L)9.0 (8.6, 9.4)Mg (mmol/L)1.9 (1.6, 2.1)Systolic pressure (mmHg)130.0 (115.0, 150.0)Diastolic pressure (mmHg)75.0 (70.0, 80.0)CP score6.0 (5.0, 9.0)MELD11.0 (8.0, 15.5)VDBP (µg/mL)160.8 (99.3, 257.9)IL-12 (pg/mL)7.5 (2.1, 8.7)TNF-a (pg/mL)4.7 (1.2, 5.7)IL-1β (pg/mL)8.0 (3.1, 11.6)IL-6 (pg/mL)7.8 (4.3, 22.0)IL-8 (pg/mL)35.7 (20.6, 90.7)IL-10 (pg/mL)3.9 (3.1, 4.7)LBP (μg/mL)10.8 (8.3, 11.4)Abbreviations: M, male; F, female; HBV, hepatis B virus; HDV, hepatis D virus; HCV, hepatis C virus; IQR, Interquartile range; Hb, Hemoglobin; Plt, Platelets; INR, International normalized ratio; SGPT, Alanine aminotransferase; G-GT, Gamma-Glutamyl Transferase; ALP, Alkaline phosphatase; CP, Child Pugh; MELD, Model for end-stage liver disease; VDBP, Vitamin D binding protein; LBP, Lipopolysaccharide binding protein.Table 2Characterization of *VDR* polymorphisms.SNP nameSNP IDSNP locationNucleotide changeCorrespondence of nomenclature of SNP allelesFokIrs2228570Exon 2C \> TF \> fBsmIrs1544410Intron 8A \> GB \> bTaqIrs731236Exon 9C \> TT \> tApaIrs7975232Intron 8A \> CA \> aAbbreviations: SNP, single nucleotide polymorphism.

Distribution of clinical variables and serum cytokine expression according to the *VDR* genotypes {#Sec3}
-------------------------------------------------------------------------------------------------

As shown in Table [3](#Tab3){ref-type="table"} the presence of BsmI polymorphism, in particular the BB genotype, was associated with advanced Child-Pugh (CP) stage (*p* = 0.044) and higher model for the end-stage liver disease (MELD) score (*p* = 0.045). The AA genotype of the ApaI polymorphism was associated with advanced CP stage (*p* = 0.001) and increased LBP levels (*p* = 0.014). The presence of TaqI polymorphism (TT genotype) was associated with advanced CP stage (*p* = 0.027) and MELD score (*p* = 0.025). As regards to the FokI polymorphism, the FF genotype was associated with lower levels of the pro-inflammatory cytokine IL-1β (*p* = 0.045).Table 3Distribution of clinical variables according to the *VDR* genotypes.BsmI A \> G (rs1544410)bbBbBBOverall*p-*value**N (%)**CP stage**0.044**A12 (45.8)32 (60.4)2 (22.2)46 (51.3)B11 (41.7)13 (23.3)2 (22.2)26 (28.9)C3 (12.5)9 (16.3)5 (55.6)17 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)20.6 (14.8, 29.6)21.5 (14.7, 31.6)29.8 (11.2, 46.7)21.1 (14.7, 31.6)0.828MELD12.0 (8.5, 17.0)10.0 (8.0, 14.0)16.0 (12.0, 19.0)11.0 (8.0, 15.5)**0.045**VDBP (μg/mL)177.6 (143.9, 259.0)136.4 (89.7, 256.7)199.3 (126.8, 209.6)160.8 (99.3, 257.9)0.307IL-12 (pg/mL)6.9 (0.0, 8.7)8.0 (5.6, 8.7)5.9 (0.0, 6.8)7.5 (2.1, 8.7)0.438TNF-a (pg/mL)4.9 (1.0, 5.9)4.6 (1.5, 5.3)5.2 (0.3, 6.0)4.7 (1.2, 5.7)0.764IL-1β (pg/mL)8.1 (6.5, 12.6)7.9 (6.2, 11.5)7.5 (0.0, 11.2)8.0 (3.1, 11.6)0.752IL-6 (pg/mL)5.8 (5.1, 12.8)7.8 (4.3, 27.2)13.0 (6.5, 49.4)7.8 (4.3, 22.0)0.520IL-8 (pg/mL)33.5 (16.0, 101.6)41.3 (23.0, 87.9)29.3 (20.9, 44.3)35.7 (20.6, 90.7)0.698IL-10 (pg/mL)3.7 (2.0, 4.2)4.0 (3.3, 5.2)4.0 (3.7, 6.3)3.9 (3.1, 4.7)0.257LBP (μg/mL)9.8 (4.9, 11.3)10.8 (8.4, 11.6)11.3 (11, 11.4)10.8 (8.3, 11.4)0.128**FokI C** \> **T (rs10735810)ffFfFFOverall*p-*** **valueN (%)**CP stage0.846A4 (42.8)21 (53)21 (51.4)46 (51.3)B4 (42.8)9 (23.5)13 (31.4)26 (28.9)C1 (14.2)9 (23.5)7 (17.2)17 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)30.3 (21.3, 46.7)22.0 (14.7, 32.2)18.4 (13.9, 26.4)21.1 (14.7, 31.6)0.139MELD12.0 (9.0, 13.0)11.0 (8.0, 16.0)11.0 (8.0, 17.0)11.0 (8.0, 15.5)0.983VDBP (μg/mL)217.8 (189.0, 282.9)147.3 (112.2, 270.4)159.3 (89.7, 220.8)160.8 (99.3, 257.9)0.355IL-12 (pg/mL)5.3 (0.0, 8.2)7.5 (5.3, 8.9)8.0 (0.0, 8.5)7.5 (2.1, 8.7)0.382TNF-a (pg/mL)4.9 (1.6, 5.8)4.6 (1.5, 5.7)4.7 (0.4, 5.7)4.7 (1.2, 5.7)0.846IL-1β (pg/mL)9.3 (7.5, 11.8)9.4 (7.4, 12.3)7.2 (0.0, 10.1)8.0 (3.1, 11.6)**0.045**IL-6 (pg/mL)5.8 (5.1, 7.7)7.8 (4.2, 20.1)9.8 (4.9, 29.4)7.8 (4.3, 22.0)0.712IL-8 (pg/mL)33.7 (20.8, 87.9)44.7 (22.6, 110.4)33.0 (20.4, 85.8)35.7 (20.6, 90.7)0.812IL-10 (pg/mL)3.7 (1.8, 4.7)3.8 (3.2, 4.6)4.0 (3.2, 4.6)3.9 (3.1, 4.7)0.970LBP (μg/mL)10.8 (9.6, 11.3)10.5 (8.7, 11.3)10.9 (4.3, 11.4)10.8 (8.3, 11.4)0.995**ApaI G** \> **T (rs7975232)aaAaAAOverall*p-*** **valueN (%)**CP stage**0.001**A3 (30)29 (63.4)13 (40)45 (51.3)B7 (60)14 (29.3)5 (16)26 (28.9)C1 (10)3 (7.3)14 (44)18 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)20.0 (9.5, 26.2)20.8 (14.9, 30.4)24.1 (14.1, 33.6)21.1 (14.7, 31.6)0.754Diastolic pressure (mmHg)60.0 (60.0, 70.0)77.5 (70.0, 90.0)77.5 (70.0, 80.0)75.0 (70.0, 80.0)**0.011**MELD9.5 (8.0, 14.0)11.0 (8.0, 14.0)13.0 (9.0, 17.0)11.0 (8.0, 15.5)0.377VDBP (μg/mL)244.9 (157.6, 288.6)170.8 (101.1, 256.7)130.2 (81.7, 215.3)160.8 (99.3, 257.9)0.140IL-12 (pg/mL)8.5 (5.1, 9.0)7.7 (0.0, 8.5)7.0 (4.7, 8.5)7.5 (2.1, 8.7)0.794TNF-a (pg/mL)5.6 (1.0, 5.9)4.4 (1.5, 5.2)5.0 (1.1, 6.1)4.7 (1.2, 5.7)0.394IL-1β (pg/mL)8.1 (0.0, 12.6)7.3 (0.0, 9.6)10.1 (7.5, 11.7)8.0 (3.1, 11.6)0.076IL-6 (pg/mL)7.7 (5.5, 12.3)5.8 (4.1, 17.6)12.9 (5.2, 29.8)7.8 (4.3, 22.0)0.177IL-8 (pg/mL)33.7 (19.9, 146.9)27.9 (19.5, 83.5)45.5 (24.4, 200.2)35.7 (20.6, 90.7)0.076IL-10 (pg/mL)3.7 (0.8, 4.0)3.9 (3.1, 4.6)4.1 (3.4, 5.4)3.9 (3.1, 4.7)0.297LBP (μg/mL)9.4 (3.8, 11.3)10.2 (4.6, 11.3)11.3 (10.5, 11.4)10.8 (8.3, 11.4)**0.014TaqI C** \> **T (rs731236)ttTtTTOverall*p-*** **valueN (%)**CP stage**0.027**A12 (42.3)33 (63.4)2 (22.2)47 (51.3)B12 (42.3)11 (22)2 (22.2)25 (28.9)C4 (15.4)8 (14.6)5 (55.6)17 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)21.2 (15.5, 30.8)20.8 (14.7, 30.3)29.8 (11.2, 46.7)21.1 (14.7, 31.6)0.719MELD12.0 (9.0, 17.0)10.0 (8.0, 14.0)16.0 (12.0, 19.0)11.0 (8.0, 15.5)**0.025**VDBP (μg/mL)175.8 (123.8, 259.0)140.5 (90.9, 259.3)199.3 (126.8, 209.6)160.8 (99.3, 257.9)0.597IL-12 (pg/mL)8.0 (0.0, 9.0)7.8 (5.4, 8.6)5.9 (0.0, 6.8)7.5 (2.1, 8.7)0.475TNF-a (pg/mL)5.2 (1.0, 5.9)4.5 (1.5, 5.3)5.2 (0.3, 6.0)4.7 (1.2, 5.7)0.595IL-1β (pg/mL)8.1 (6.5, 12.6)7.9 (3.1, 11.6)7.5 (0.0, 11.2)8.0 (3.1, 11.6)0.786IL-6 (pg/mL)7.7 (5.1, 13.8)7.6 (4.3, 23.6)13.0 (6.5, 49.4)7.8 (4.3, 22.0)0.569IL-8 (pg/mL)33.7 (16.0, 101.6)41.3 (22.9, 90.7)29.3 (20.9, 44.3)35.7 (20.6, 90.7)0.759IL-10 (pg/mL)3.8 (2.0, 4.4)3.9 (3.3, 5.0)4.0 (3.7, 6.3)3.9 (3.1, 4.7)0.468LBP (μg/mL)10.2 (5.2, 11.3)10.7 (8.2, 11.4)11.3 (11.0, 11.4)10.8 (8.3, 11.4)0.200Abbreviations: IQR, Interquartile range; CP, Child Pugh; MELD, Model for end-stage liver disease; VDBP, Vitamin D binding protein; LBP, Lipopolysaccharide binding protein.
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As shown in Table [4](#Tab4){ref-type="table"}, BsmI patients harboring the BB genotype had higher MELD score (*p* = 0.026) and were mainly at CP stage C (*p* = 0.020) compared to Bb/bb genotypes. ApaI patients harboring the AA genotype had increased levels of LBP (*p* = 0.004), IL-1β (*p* = 0.036) and IL-8 (*p* = 0.03) and were mostly at CP stage C (*p* = 0.001) compared to patients with the Aa/aa genotypes. The TT genotype carriers of the TaqI polymorphism had higher MELD score (*p* = 0.026) and were mainly at CP stage C (*p* = 0.02). Finally, FokI patients who had the FF genotype showed lower levels of IL-1β (*p* = 0.013) compared to patients with the Ff/ff genotypes. In the multivariate analysis, in the presence of other significant covariates, as well as cirrhosis' etiology, AA genotype of ApaI polymorphism \[OR: 5.5; 95% CI (1.3, 22.9), *p* = 0.019\], BB genotype of BsmI polymorphism \[OR: 9.6; 95% CI (1.3, 72.20), *p* = 0.027\] and TT genotype of TaqI polymorphism \[OR: 9.6; 95% CI (1.3, 72.20), *p* = 0.027\] were found to be associated with increased odds of more advanced CP stage when compared to Aa/aa, Bb/bb and Tt/tt genotypes respectively (Table [5](#Tab5){ref-type="table"}). FF genotype of FokI polymorphism was not found to be a significant predictor of disease severity.Table 4Comparisons of clinical parameters and serum cytokine expression between *VDR* polymorphisms.BsmI A \> G (rs1544410)Bb + bbBBOverall*p-*value**N (%)**CP stage**0.020**A44 (55.3)2 (22.2)46 (51.3)B24 (29.8)2 (22.2)26 (28.9)C12 (14.9)5 (55.6)17 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)21.0 (14.8, 30.3)29.8 (11.2, 46.7)21.1 (14.7, 31.6)0.540VDBP (μg/mL)157.6 (97.4, 259.0)199.3 (126.8, 209.6)160.8 (99.3, 257.9)0.890MELD11.0 (8.0, 14.0)16.0 (12.0, 19.0)11.0 (8.0, 15.5)**0.026**IL-12 (pg/mL)7.9 (5.1, 8.7)5.9 (0.0, 6.8)7.5 (2.1, 8.7)0.225TNF-a (pg/mL)4.6 (1.3, 5.7)5.2 (0.3, 6.0)4.7 (1.2, 5.7)0.804IL-1β (pg/mL)8.1 (6.2, 11.8)7.5 (0.0, 11.2)8.0 (3.1, 11.6)0.593IL-6 (pg/mL)7.7 (4.3, 18.1)13.0 (6.5, 49.4)7.8 (4.3, 22.0)0.298IL-8 (pg/mL)37.7 (20.4, 93.4)29.3 (20.9, 44.3)35.7 (20.6, 90.7)0.778IL-10 (pg/mL)3.8 (3.1, 4.6)4.0 (3.7, 6.3)3.9 (3.1, 4.7)0.449LBP (μg/mL)10.5 (7.0, 11.4)11.3 (11.0, 11.4)10.8 (8.3, 11.4)0.121**FokI C** \> **T (rs10735810)Ff + ffFFOverall*p-*** **valueN (%)**CP stage0.829A25 (51.2)21 (51.5)46 (51.3)B13 (26.8)13 (31.4)26 (28.9)C10 (22)7 (17.1)17 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)22.8 (15.9, 33.3)18.4 (13.9, 26.4)21.1 (14.7, 31.6)0.206VDBP (μg/mL)168.9 (113.7, 270.6)159.3 (89.7, 220.8)160.8 (99.3, 257.9)0.309MELD11.0 (8.0, 15.0)11.0 (8.0, 17.0)11.0 (8.0, 15.5)0.867IL-12 (pg/mL)7.0 (4.2, 8.9)8.0 (0.0, 8.5)7.5 (2.1, 8.7)0.840TNF-a (pg/mL)4.6 (1.5, 5.7)4.7 (0.4, 5.7)4.7 (1.2, 5.7)0.580IL-1β (pg/mL)9.3 (7.4, 12.3)7.2 (0.0, 10.1)8.0 (3.1, 11.6)**0.013**IL-6 (pg/mL)7.1 (4.2, 17.6)9.8 (4.9, 29.4)7.8 (4.3, 22.0)0.459IL-8 (pg/mL)38.1 (20.8, 110.4)33.0 (20.4, 85.8)35.7 (20.6, 90.7)0.555IL-10 (pg/mL)3.8 (3.0, 4.7)4.0 (3.1, 4.6)3.9 (3.1, 4.7)0.907LBP (μg/mL)10.5 (9.0, 11.3)10.9 (4.3, 11.4)10.8 (8.3, 11.4)0.983**ApaI A** \> **C (rs7975232)Aa** + **aaAAOverall*p-*** **valueN (%)**CP stage**0.001**A32 (56.9)13 (40)45 (51.3)B20 (35.3)5 (16)25 (28.9)C5 (7.8)14 (44)19 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)20.6 (14.8, 30.3)24.1 (14.1, 33.6)21.1 (14.7, 31.6)0.527VDBP (μg/mL)178.9 (123.4, 260.4)130.2 (81.7, 215.3)160.8 (99.3, 257.9)0.161MELD11.0 (8.0, 14.0)13.0 (9.0, 17.0)11.0 (8.0, 15.5)0.167IL-12 (pg/mL)7.8 (0.0, 8.7)7.0 (4.7, 8.5)7.5 (2.1, 8.7)0.704TNF-a (pg/mL)4.5 (1.3, 5.6)5.0 (1.1, 6.1)4.7 (1.2, 5.7)0.258IL-1β (pg/mL)7.5 (0.0, 11.4)10.1 (7.5, 11.7)8.0 (3.1, 11.6)**0.036**IL-6 (pg/mL)6.5 (4.1, 13.3)12.9 (5.2, 29.8)7.8 (4.3, 22.0)0.063IL-8 (pg/mL)29.8 (19.6, 84.4)45.5 (24.4, 200.2)35.7 (20.6, 90.7)**0.030**IL-10 (pg/mL)3.8 (3.0, 4.5)4.1 (3.5, 5.5)3.9 (3.1, 4.7)0.221LBP (μg/mL)9.9 (4.8, 11.3)11.3 (10.5, 11.4)10.8 (8.3, 11.4)**0.004TaqI C** \> **T (rs731236)Tt + ttTTOverall*p-*** **valueN (%)**CP stage**0.020**A44 (55.3)2 (22.2)46 (51.3)B24 (29.8)2 (22.2)26 (28.9)C12 (14.9)5 (55.6)17 (19.8)**Median (IQR)**Vitamin D levels (ng/mL)21.0 (14.8, 30.3)29.8 (11.2, 46.7)21.1 (14.7, 31.6)0.540VDBP (μg/mL)157.6 (97.4, 259.0)199.3 (126.8, 209.6)160.8 (99.3, 257.9)0.890MELD11.0 (8.0, 14.0)16.0 (12.0, 19.0)11.0 (8.0, 15.5)**0.026**IL-12 (pg/mL)7.9 (5.1, 8.7)5.9 (0.0, 6.8)7.5 (2.1, 8.7)0.225TNF-a (pg/mL)4.6 (1.3, 5.7)5.2 (0.3, 6.0)4.7 (1.2, 5.7)0.804IL-1β (pg/mL)8.1 (6.2, 11.8)7.5 (0.0, 11.2)8.0 (3.1, 11.6)0.593IL-6 (pg/mL)7.7 (4.3, 18.1)13.0 (6.5, 49.4)7.8 (4.3, 22.0)0.298IL-8 (pg/mL)37.7 (20.4, 93.4)29.3 (20.9, 44.3)35.7 (20.6, 90.7)0.778IL-10 (pg/mL)3.8 (3.1, 4.6)4.0 (3.7, 6.3)3.9 (3.1, 4.7)0.449LBP (μg/mL)10.5 (7.0, 11.4)11.3 (11.0, 11.43)10.8 (8.3, 11.4)0.121Abbreviations: IQR, Interquartile range; CP, Child Pugh; MELD, Model for end-stage liver disease; VDBP, Vitamin D binding protein; LBP, Lipopolysaccharide binding protein.Table 5Multivariate analysis for the association of VDR polymorphisms with cirrhosis severity by means of CP stage.Factor*OR*95% C.I.*p*-valueSNP_ApaI  Aa + aa\*1  AA5.51(1.33, 22.89)0.019Etiology  alcohol^\*^1  viral5.01(1.11, 22.71)0.036  other11.74(1.34, 102.94)0.026Sex  male\*1  female0.10(0.02, 0.53)0.007VDBP  per unit0.98(0.97, 0.99)\<0.001IL-8  per unit1.01(1.00, 1.02)0.005LBP  per unit1.02(1.00, 1.05)0.031SNP_BsmI  Bb + bb\*1  BB9.64(1.29, 72.20)0.027Etiology  alcohol\*1  viral3.66(0.89, 15.05)0.072  other7.78(0.94, 64.15)0.057Sex  male\*1  female0.12(0.02, 0.62)0.012VDBP  per unit0.98(0.97, 0.99)\<0.001IL-8  per unit1.01(1.00, 1.02)0.003LBP  per unit1.02(1.00, 1.05)0.031SNP_TaqI  Tt + tt\*1  TT9.64(1.29, 72.20)0.027Etiology  alcohol\*1  viral3.66(0.89, 15.05)0.072  other7.78(0.94, 64.15)0.057Sex  male\*1  female0.12(0.02, 0.62)0.012VDBP  per unit0.98(0.97, 0.99)\<0.001IL-8  per unit1.01(1.00, 1.02)0.003LBP  per unit1.02(1.00, 1.05)0.031SNP_FokI  Ff + ff\*1  FF0.45(0.14, 1.49)0.191Etiology  alcohol\*1  viral3.15(0.77, 12.86)0.111  other5.22(0.81, 33.69)0.082Sex  male\*1  female0.12(0.03, 0.58)0.008VDBP  per unit0.98(0.97, 0.99)\<0.001IL-8  per unit1.01(1.00, 1.02)0.004LBP  per unit1.03(1.01, 1.06)0.011\*Reference category.Abbreviations: OR, odds ratio; C.I., confidence interval; SNP, single nucleotide polymorphism; VDBP, vitamin D binding protein; LBP, lipopolysaccharide binding protein.

*VDR* polymorphisms and the etiology of liver cirrhosis {#Sec5}
-------------------------------------------------------

The grouping of cirrhotic population according to disease etiology was performed as follows: patients with cirrhosis of viral origin (n = 40, 44.2%), alcoholic origin (n = 32, 36.4%) and other etiologies (n = 17, 19.4%). None of the *VDR* polymorphisms interacted significantly with the etiology of the disease, indicating that the effect of the polymorphisms is similar across all groups regarding cirrhosis' etiology.

Association between vitamin D and VDBP levels with VDR polymorphisms {#Sec6}
--------------------------------------------------------------------

We found no statistically significant differences between serum 25(OH) vitamin D levels and VDBP levels in relation to *VDR* polymorphisms.

Linkage disequilibrium of *VDR* polymorphisms in cirrhotic patients {#Sec7}
-------------------------------------------------------------------

Linkage disequilibrium analysis revealed very strong LD between BsmI and TaqI (D' = 0.999), BsmI and ApaI (D' = 0.999) and TaqI and ApaI (D' = 0.999) polymorphisms. In contrast, very weak LD was detected between FokI and BsmI (D' = 0.088), FokI and TaqI (D' = 0.063), FokI and ApaI (D' = 0.014) polymorphisms (Fig. [1](#Fig1){ref-type="fig"}).Figure 1(**A**) Structure of genomic region of the *VDR* gene on chromosome 12q13.11. (**A**) The black boxes demonstrate the exons of the *VDR* gene. The approximate locations of the examined polymorphisms are indicated by arrows. (**B**) Schematic representation of pairwise linkage disequilibrium (LD) pattern. (**A**) LD pattern of the *VDR* gene polymorphisms \[BsmI A \> G (B \> b), ApaI A \> C (A \> a), TaqI C \> T (T \> t) and FokI C \> T (F \> f)\] in the studied population (n = 89). Each square represents the D' values and the p values between the pairs of polymorphisms. The intensity of the dark color of the blocks is proportional to the D' value, indicating the strength LD between polymorphisms. Black boxes, high LD; white boxes, low LD.

Haplotype analysis of VDR polymorphisms in relation to disease severity {#Sec8}
-----------------------------------------------------------------------

Haplotype association with cirrhosis severity was evaluated by the distribution of VDR haplotypes in the different CP stages. Estimated VDR haplotype frequencies of FokI, BsmI, ApaI and TaqI polymorphisms are reported in Table [6](#Tab6){ref-type="table"}. The results showed that in patients with CP stage C, BAT haplotype was more frequent suggesting a potential increased risk for advanced cirrhosis, whereas the complementary haplotype bat was more common in patients with CP stage A; however, this difference was no significant (LR test *p* = 0. 581).Table 6Haplotype frequencies and association with cirrhosis severity.HaplotypesCP stageABCnFrequency (%)nFrequency (%)nFrequency (%)BAT3519.7158.52011.2bat3720.82413.573.9bAt1810.1105.6105.6BAt00.010.0110.01baT00.000.000.0bAT00.000.000.0Bat00.000.000.0BaT00.000.000.0Abbreviations: CP stage, Child-Pugh stage.

Survival analysis {#Sec9}
-----------------

The cumulative mortality rate was 31.46% (28 out of 89 patients), after a median follow-up of 16 months (IQR: 3--40 months). The main causes of mortality were liver failure (n = 19, 67.9%), HCC (n = 4, 14.3%), renal failure (n = 3, 10.7%), bleeding (n = 1, 3.6%) and other causes (n = 1, 3.6%). In the univariable Cox regression analysis, the following factors were found to be significantly associated with mortality: CP score (*p* \< 0.001), MELD (*p* \< 0.001), VDBP levels (*p* = 0.003), IL-6 (*p* = 0.016), IL-8 (*p* = 0.001), LBP levels (*p* = 0.020) and the CP stage III (*p* \< 0.001). In the multivariate analysis, CP score \[HR: 1.26, 95% CI (1.02--1.56) *p* = 0.035\], MELD \[HR: 1.15, 95% CI (1.03--1.28) *p* = 0.012\] and the presence of FF genotype \[ff genotype vs FF: HR = 0.22 95% CI (0.06--0.77), *p* = 0.018)\] were significant independent prognostic factors for patient survival (Table [7](#Tab7){ref-type="table"}).Table 7Univariate and multivariate cox regression analyses for cirrhotic patients' survival.*FactorHR*95% C.I.*p*-valueUnivariate analysis**CP score**per unit1.47(1.26, 1.71)**\<0.001MELD**per unit1.20(1.11, 1.29)**\<0.001VDBP**per unit0.99(0.99, 1.00)**0.003IL-12**per unit1.02(0.98, 1.06)0.287**TNF-a**per unit1.04(0.94, 1.17)0.440**IL-1β**per unit1.00(0.97, 1.04)0.827**IL-6**per unit1.00(1.00, 1.00)**0.016IL-8**per unit1.00(1.00, 1.00)**0.001IL-10**per unit1.01(0.98, 1.04)0.455**LBP**per unit1.02(1.00, 1.04)**0.020Age**per unit1.01(0.98, 1.05)0.438**Sex**Male\*1Female1.16(0.50, 2.71)0.735**CP stage**A\*1B2.87(0.99, 8.33)0.052C9.06(3.19, 25.76)**\<0.001SNP_BsmI**bb\*1Bb0.55(0.24, 1.30)0.175BB1.81(0.67, 4.86)0.242**SNP_TaqI**tt\*1Tt0.60(0.26, 1.42)0.249TT1.92(0.71, 5.18)0.195**SNP_FokI**ff\*1Ff0.72(0.26, 2.03)0.538FF0.51(0.18, 1.46)0.210**SNP_ApaI**aa\*1Aa1.21(0.27, 5.41)0.803AA2.11(0.48, 9.21)0.323***Factor**HR*95% C.I.*p*** **-** **valueMultivariate analysisCP score**per unit1.26(1.02, 1.56)**0.035MELD**per unit1.15(1.03, 1.28)**0.012SNP_FokI**ff\*1Ff0.37(0.12, 1.13)0.080FF0.22(0.06, 0.77)**0.018**\*Reference category.Abbreviations: HR, hazard ratio; C.I., confidence interval; CP, child pugh; MELD, model for end-stage liver disease; VDBP, vitamin D binding protein; LBP, lipopolysaccharide binding protein; SNP, single nucleotide polymorphism.

Discussion {#Sec10}
==========

This is the first report of an association between polymorphisms of the *VDR* gene and cytokine levels, severity of liver disease and survival in patients with liver cirrhosis. In particular, an independent association between BsmI, ApaI, and TaqI *VDR* polymorphisms and the severity of liver cirrhosis is clearly shown. Moreover, the presence of FF genotype of FokI polymorphism is associated with a better prognosis regarding survival in this cohort. These features appear to be independent of the etiology of liver cirrhosis, as they observed in patients of any cause.

Vitamin D promotes the stimulation of innate immunity, the differentiation of monocytes, the inhibition of lymphocyte proliferation and cytokine secretion by T and B cells^[@CR22],[@CR23]^. *VDR* acts as a ligand-stimulated transcription factor and activates 1,25(OH)~2~D~3~ at the transcriptional level. The activation of *VDR* contributes to the regulation of immune response by inhibiting T helper 1 (Th1) cell proliferation and pro-inflammatory cytokine production and inducing Th2 cell proliferation and anti-inflammatory cytokine production^[@CR7],[@CR22]--[@CR26]^. The presence of *VDR* polymorphisms possibly leads to a dysfunctional receptor, affecting VDR activity and the subsequent vitamin D-mediated effects^[@CR26]^.

The association between *VDR* polymorphisms and the occurrence of chronic liver disease from different etiologies such as autoimmune hepatitis, PBC, HCC or HBV infection has been investigated with conflicting results^[@CR8],[@CR10]--[@CR16],[@CR27]^. Previous reports have identified gene polymorphisms which affect the progression of liver fibrosis^[@CR28]--[@CR31]^. The relationship between liver fibrosis progression and the presence of *VDR* polymorphisms (ApaI, TaqI and BsmI) has been investigated, indicating that in PBC patients, BsmI and TaqI were associated with progressive cirrhosis^[@CR10]^ and in NAFLD patients, *VDR* mRNA expression and profibrogenic genes were significantly affected by BsmI polymorphism^[@CR18]^. The effect of bAt haplotype in fibrosis progression has been investigated in HCV patients as well, giving conflicting results^[@CR18],[@CR19],[@CR32]^. Our results indicate that the presence of ApaI polymorphism (AA genotype) is related to significant higher levels of IL-1β and IL-8. The increased levels of these pro-inflammatory cytokines suggest that the ApaI *VDR* polymorphism leads to a less active VDR protein which may contribute to a disturbance of Th1/Th2 balance, a transition to Th1 polarization and a decreased activity of vitamin D-related signaling pathways.

Several studies have demonstrated a positive correlation between higher pro-inflammatory cytokine levels and the severity of liver disease^[@CR33]--[@CR37]^. In this study, we have shown that the AA genotype of the ApaI polymorphism is related to decreased levels of platelets and increased levels of LBP, which are consistent with the progression of cirrhosis and portal hypertension development^[@CR38],[@CR39]^. The presence of ApaI, TaqI and BsmI *VDR* polymorphisms could impede the interaction between vitamin D and VDR, resulting in ineffective vitamin D-VDR complex, impaired VDR-mediated transcription, decreased activity of vitamin D related signaling pathways, transition to a Th1 polarization, and consequently, to a more progressive form of liver cirrhosis (Fig. [2](#Fig2){ref-type="fig"}).Figure 2Schematic representation illustrating our proposed mechanism of how ApaI *VDR* polymorphisms potentially affect the progression of liver cirrhosis. (**a**) Presence of Aa/aa genotypes of ApaI *VDR* polymorphism. *VDR* is an intracellular ligand-activated transcription factor that specifically binds 1,25(OH)2D~3~ and regulates the expression of several target genes. Upon the activation of vitamin D, the ligated VDR heterodimerizes with retinoid X receptor (RXR) which is necessary for DNA binding, translocates to the nucleus, binds to vitamin D response elements (VDRE) and recruits other nuclear proteins to the transcriptional pre-initiation complex. This process results in the transcriptional activation or suppression of the target genes through the interaction with nuclear receptor co-activators or co-repressors. The binding of VDR with vitamin D may modulate cytokine responses by T cells, inhibiting Th1 cell proliferation and pro-inflammatory cytokine secretion and activating Th2 cell proliferation and anti-inflammatory cytokine secretion. (**b**) Presence of AA genotype of ApaI *VDR* polymorphism. The presence of polymorphisms may impair the activity of the *VDR* resulting in a dysfunctional receptor. The dimerization of the 1,25(OH)2D~3~-VDR with RXR may be hindered by the existence of genetic variations thus affecting VDR activity and subsequent downstream vitamin D-mediated effects. This impaired process may lead to disturbance of the Th1/Th2 balance, resulting in a transition to Th1 cell response and pro-inflammatory cytokine secretion that is closely related the progression of liver cirrhosis.

A second novel finding of this study, is the inverse association between the FokI polymorphism, particularly the FF genotype, with mortality in liver cirrhotic patients, imparting a protective role of this genotype in cirrhosis. The FokI polymorphism is located in the coding region of the *VDR* gene and results in a VDR protein with a different structure, creating a new start codon and consequently a VDR protein shortened by three amino acids^[@CR38],[@CR40]^. This protein is more functional and has higher transcriptional activity compared to the long-length VDR protein^[@CR38],[@CR40],[@CR41]^. FokI is the only polymorphism that was not associated with severity of liver cirrhosis in our study. The length of the VDR protein influences the regulation of gene transcription through occupation of recognition sites of other transcription factors and interference with their signaling pathways^[@CR7]^. Therefore, a longer VDR protein may lead to a decreased transcriptional activity and an increased risk of susceptibility to disease^[@CR40]^. These observations are in line with our study as we have shown that the presence of FokI polymorphism (FF genotype) is associated with significantly lower levels of IL-1β. Patients with the FF genotype produce a shorter form of VDR, leading to higher transcriptional activity, formation of more active complexes of VDR-vitamin D, inhibition of the Th1 response and induction of the Th2 cell response. Hence, patients with FokI FF genotype may have a better response to vitamin D resulting in a lower progression rate of cirrhosis. However, due to the fact that this hypothesis is of high interest, we suggest that it should be further explored in larger and more specific cohorts with more patients harboring the FokI polymorphism in order to be confirmed.

We have also shown the existence of strong linkage disequilibrium between the BsmI, ApaI and TaqI polymorphic sites in our cirrhotic population. These results are in agreement with previous reports suggesting an extensive LD between these genetic markers^[@CR10],[@CR14]^. As these polymorphisms are in strong LD, it can be assumed that these single nucleotide polymorphisms (SNPs) contribute to the severity of cirrhosis in a dependent manner. Nevertheless, as these polymorphisms do not cause a functional change in the *VDR* gene, it is possible that BsmI, TaqI and ApaI are possibly genetic markers of other functional variations of the *VDR* gene or in other closely linked genes that are in linkage disequilibrium with the identified polymorphisms.

Some limitations of the current study should be acknowledged. The first limitation concerns the relatively small sample size, however our results are consistent with the reports on the association between *VDR* polymorphisms and the susceptibility to liver fibrosis^[@CR10],[@CR18],[@CR19]^. Secondly, our study was performed on Caucasians patients and it would be interesting to perform the same analysis in different ethnic groups. Lastly, the single measurement of 25(OH)D at baseline may not be representative of the respective concentrations over time. However, there are reports supporting that although 25(OH)D levels present seasonal fluctuation, its levels remain stable over time^[@CR42],[@CR43]^.

In conclusion, our results indicate that *VDR* polymorphisms are independently associated with the severity of liver cirrhosis and the survival of patients with liver disease, regardless of disease etiology, suggesting a potential influence of them in disease progression. Based on these results future studies will delineate causation between specific *VDR* polymorphisms and outcome/severity of liver cirrhosis, and the importance of *VDR* polymorphism analysis in clinical practice to identify patients at greater risk of disease progression and to modify patients' surveillance and treatment accordingly.

Methods {#Sec11}
=======

Study design and participants {#Sec12}
-----------------------------

This study was a prospective cohort study, on 89 consecutive Caucasian patients with liver cirrhosis. During the recruitment, all cirrhotic patients were in stable clinical condition, without any severe complication of liver disease including gastro-intestinal bleeding, hepatorenal syndrome, moderate to severe hepatic encephalopathy, spontaneous bacterial peritonitis, malignancy, or organ failure. Patients with indications or history of bacterial infection at last 4 weeks prior to recruitment in the study, human immunodeficiency virus (HIV) infection and severe cardiopulmonary disease or renal failure were excluded. Severity of cirrhosis was assessed by the CP stage and the MELD score^[@CR44]^. Diagnosis of cirrhosis was based on histological or compatible clinical, laboratory and imaging data^[@CR45]--[@CR47]^. After baseline examination, patients were followed in the hepatology clinic at regular intervals according to current guidelines^[@CR48]^ until death, liver transplantation or completion of the study. The recruitment of the patients was performed at the University Hospital of Patras (Patras, Greece) between September 2009 and April 2013. Blood samples from all patients were collected throughout the year. Seasonal variability was defined as winter/spring from December to April and summer/autumn from May to October^[@CR49]^. Sampling occurred mostly in winter/spring (70%) compared to summer/autumn (30%). All study participants, or their legal guardian, provided informed written consent prior to study enrollment. The study protocol was approved by Patras University Hospital Scientific Review Board and Ethics Committee. The Hospital abides by the 1975 Helsinki declaration on ethical principles for medical research involving human subjects. Further all the experiments were performed in accordance with relevant guidelines and regulations of the concerned ethical committee.

Vitamin D assay {#Sec13}
---------------

Serum samples were collected from the patients and stored at −80 °C until analysis. Serum 25(OH)D levels were determined using a 25(OH)D vitamin D ELISA kit for serum and plasma (Enzo Life Sciences, NY, USA), according to the manufacturer's instructions. Currently accepted standards for the definition of Vitamin D status are: optimal vitamin D levels ≥30 ng/mL, vitamin D deficiency ≤20 ng/mL and vitamin D insufficiency between 20 and 30 ng/mL^[@CR50],[@CR51]^.

VDBP and LBP assays {#Sec14}
-------------------

Serum VDBP levels were determined using a human Vitamin D BP Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA), and serum LBP levels using a human LBP ELISA kit (SunRed Biological Technology, Shanghai). Data analysis was performed using the Curve Expert 1.4 software.

Cytokine Assays {#Sec15}
---------------

Serum interleukin-12 **(**IL-12), IL-1β, IL-6, IL-8, IL-10 and tumor necrosis factor alpha (TNF-a) levels were determined using a Cytometric Bead Array (CBA) assay (Human Inflammatory Cytokines Kit, BD Biosciences, San Diego, CA, USA) run on a BD FACS Array Bioanalyzer. Data were analyzed using the FlowJo V7.5 software (Tree Star Inc., Ashland, OR, USA).

DNA extraction {#Sec16}
--------------

Genomic DNA was extracted using the NucleoSpin® Blood QuickPure kit (Macherey-Nagel, Germany). The DNA concentration of the samples was determined using a Nanodrop spectrophotometer (UV spectrophotometer Q3000, Quawell Technology, Inc., USA).

*VDR* Genotyping {#Sec17}
----------------

Genotyping was carried out using TaqMan SNP Genotyping Assays (Applied Biosystems; Foster City, USA). The PCR reactions were carried out in MicroAmp® Fast Optical 96-Well Reaction Plates (Applied Biosystems) on the Step One Plus real-time PCR system (Applied Biosystems, CA, USA). The rs731236 (TaqI), rs1544410 (BsmI), rs7975232 (ApaI) and rs2228570 (FokI) probes were designed using TaqMan pre-designed SNP genotyping assays (Applied Biosystems). Two non-template-control wells were included on each plate. DNA amplification was performed as follows: 95 °C for 10 min, followed by 40 cycles of 92 °C for 15 sec and 60 °C for 1 min.

Statistical analysis {#Sec18}
--------------------

Continuous variables were summarized as medians and interquartile ranges (IQRs) while counts and corresponding percentages were calculated for categorical variables. All comparisons were performed using non-parametric tests: Fisher's exact tests in case of frequencies' comparisons, Mann-Whitney and Kruskal-Wallis tests for the comparison of median values between two groups and more than two groups, respectively. Correlations between vitamin D and VDBP levels with *VDR* polymorphisms were assessed by the Spearman's coefficient. Multivariable ordinal logistic regression models were fitted, to test the hypothesis that the *VDR* polymorphisms are associated with the CP stage. Further analysis was conducted to explore whether these polymorphisms' effect interacts with the etiology of cirrhosis, i.e. whether the effect of the polymorphisms is different in the subgroups of viral, alcoholic or other etiology's cirrhosis. The *VDR* gene polymorphisms' Hardy-Weinberg equilibrium was examined by means of chi square test goodness of fit test, i.e by comparing observed and expected count in each of the polymorphisms groups (wt/wt, mt/wt, mt/mt). Pairwise linkage disequilibrium (LD) analysis between the *VDR* gene polymorphisms was performed using the genetics package of R software. Allelic frequencies were estimated by the hapipf stata command, based on the expectation-maximization (EM) algorithm. The hypothesis of allelic association with the CP stage was tested using the likelihood-ratio (LR) test. Time to death was analyzed using the Cox survival model. Before fitting the models, the proportional hazards assumption was assessed for all variables based on Schoenfeld residuals. Individuals' baseline clinical and laboratory variables, including the *VDR* polymorphisms, were considered as potential risk factors. For all models selection, the Collett's approach was followed^[@CR52]^. More specifically, all variables with a *p*-value \< 0.200 were initially included and then eliminated using backwards selection. When a model that included only significant covariates was reached, variables initially excluded entered the final model one by one and tested for significance in the presence of already included significant variables. Analysis was performed using Stata 13.1 (StataCorp LP, College Station, Texas, USA). Level of significance α was set at 0.05.
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